News | oneAMYLOIDOSISvoice

With $130M, Protego pushes forward a new type of amyloidosis drug

Knowing where to go for information when diagnosed with Amyloidosis is key. This is a difficult disease from a diagnosis standpoint, and getting it right is…

Amyloidosis Support Groups (ASG) Launches new Amyloidosis Patient Registry

The Amyloidosis Patient Registry is a new resource for the entire amyloidosis community from Amyloidosis Support Groupsexternal link, opens in a new tab. By…

Alnylam Pharmaceuticals Announces Initiation of APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company has initiated APOLLO-B, a global Phase 3…

Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting

Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), presented data today from the…

oneAMYLOIDOSISvoice.com Support Group Platform Begins Empowering the Amyloidosis Community With Invaluable Info About Amyloidosis

U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved both VYNDAQEL(R) (tafamidis meglumine) and VYNDAMAX(tm) (tafamidis) for…

HealthWell Foundation Opens New Amyloidosis Fund to Assist Patients With Treatment Costs

New, More Accessible Staging System Developed to Predict Survival for Patients With Light Chain Amyloidosis

A new staging system developed with a more accessible test to predict the chance of survival in patients living with light chain (AL) amyloidosis. Led by…

Molecules That Curb Errant Proteins of AL Amyloidosis Point to New Type of Therapy

Scientists at Scripps Research have identified a group of small molecules that prevent structural changes to proteins that are at the root of AL amyloidosis, a…

Tegsedi™ to be Available on the NHS for hATTR Amyloidosis

Akcea Therapeutics UK Ltd., has announced that NICE has issued a positive Final Evaluation Document (FED) for Tegsedi(tm) (inotersen) for the treatment of stage 1…

Subscribe to